Nicotine vaccine is set to stub out smoking
SCIENTISTS will today unveil results from the first large-scale human trial into a vaccine for nicotine which could see people immunised against addictions to smoking within the next five years.
A Swiss pharmaceutical company will reveal the outcome of a six-month vaccine trial of 300 volunteers, all of whom were heavy smokers before receiving injections to counter the habit.
Addiction experts said last night that the closely-guarded results, which are to be set out at the American Society of Clinical Oncology?s annual meeting in Orlando, Florida, were likely to be positive and could prove a watershed in the quest to introduce a nicotine vaccine.
Cytos Biotechnology is the first to report back on a large group trial of the drug, but two other firms, including Cambridge-based Xenova Research, are to launch similar studies imminently.
The three trial drugs, which are taken as a course of between four and six injections, work by stimulating the production of antibodies in the blood. These antibodies stop nicotine from entering the brain and producing the addictive sensation craved by smokers.
The body?s immune system does not normally react to nicotine, but scientists have combined the chemical with a protein to trigger a ?blocking? response. The antibodies which are produced attach themselves to nicotine circulating in the bloodstream, forming a compound that is to big to cross into the brain.
Early trials in mice and small-scale human studies have shown that the vaccine can significantly reduce the euphoric rush of both nicotine and cocaine.
A spokesman for Cytos said that the six-month results, which were finalised this week, would provide proof of concept not only for a nicotine vaccine, but other vaccines for conditions such as asthma and Alzheimer?s using similar antibody responses.
Campbell Bunce, an immunologist working for Xenova, said that he expected Cytos?s findings for its vaccine to be positive. He said that even if it did not live up to expectations, the vaccine could still prove a very important weapon against smoking used in combination with other anti-addiction treatments such as nicotine patches, gum and antidepression drugs.
Every year in the UK around 114,000 people die as a result of smoking ? a fifth of all UK deaths ? with lung cancer, coronary heart disease and chronic obstructive lung disease claiming most lives. Around 13 million adults in Britain smoke cigarettes ? 28 per cent of men and 26 per cent of women ? while one in ten teenagers is categorised as a regular smoker. For both sexes, the proportion of adults who smoke is highest in those aged 20 to 24.
The NHS spent £32.3 million to help smokers to quit in the eight months to December.
?We are making real steps forward,? Dr Bunce said. ?I am very optimistic about the vaccines. I think they have a very good chance of working. We have seen that smokers who have received the vaccine do report a definite reduced sense of pleasure from cigarettes when on vaccines.?
Research from a small-scale trial confirmed such conclusions. A total of 60 subjects who smoked between 10 and 75 cigarettes a day were divided into three cohorts. In the placebo group, just 8 per cent of volunteers were still not smoking cigarettes after 12 months, compared with more than a third of those in one group receiving a high dose of the vaccine.
Deborah Arnott, director of Action on Smoking and Health, said that vaccines offered the chance for a major advance.
But although the West might benefit, the rest of the world would probably be neglected because of the expense. ?We still have to worry about stopping people from becoming addicted to smoking in the first place,? she said.